Page last updated: 2024-11-11

gw 4064

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9893571
CHEMBL ID318457
CHEBI ID79997
CHEBI ID93125
SCHEMBL ID3996233
MeSH IDM0369044

Synonyms (64)

Synonym
HY-50108
BRD-K64245000-001-01-7
gtpl2743
3-[(e)-2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]ethenyl]benzoic acid
278779-30-9
gw 4064 ,
gw-4064
3-[(e)-2-(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methoxy}phenyl)ethenyl]benzoic acid
bdbm21724
3-[(e)-2-(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-(1-methylethyl)isoxazol-4-yl]methoxy}phenyl)ethenyl]benzoic acid
chembl318457 ,
NCGC00167739-01
gw4064 ,
C412815 ,
benzoic acid, 3-(2-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl)methoxy)phenyl)ethenyl)-
chebi:79997 ,
AKOS005146035
SCHEMBL3996233
NCGC00167739-02
EX-8455
gw-4064x
1089660-72-9
(e)-3-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)styryl)benzoic acid
A15107
BCP9000747
BCP0726000129
3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]-benzoic acid
3DCT
CS-0304
S2782
benzoic acid, 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]-
BRD-K88186167-001-01-4
292047-56-4
smr004702991
MLS006011231
unii-sr225wuz0h
sr225wuz0h ,
3-(2,6-dichlorophenyl)-4-(3'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole
3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid
AC-31465
3-[2-[2-chloro-4-[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-ylmethoxy]phenyl]vinyl]benzoic acid
J-519753
CHEBI:93125
gw4064, >=97% (hplc)
AS-74916
3-[2-(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methoxy}phenyl)ethenyl]benzoic acid
J-016908
SW203830-2
NCGC00167739-05
4-hydroxy-5-fluoro-6-ethylpyrimidine
EX-A1383
3-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)styryl)benzoic acid
HMS3677B05
Q27077943
HMS3413B05
3-[(e)-2-(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-(2-propanyl)-1,2-oxazol-4-yl]methoxy}phenyl)ethenyl]benzoic acid
DTXSID101017083
AMY9044
CCG-264997
AKOS037647822
A857634
3-(2,6-dichlorophenyl)-4-(3'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole;gw4064
F14677
3-[(1e)-2-(2-chloro-4-{[3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methoxy}phenyl)ethenyl]benzoic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This report of hepatobiliary injury following GW4064 exposure extends previous investigations of the intrahepatic biliary system in medaka, reveals sensitivity to toxicant exposure, and illustrates the need for added resolution in detection and interpretation of toxic responses in this vertebrate."( Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes).
Hinton, DE; Howarth, DL; Kullman, SW; Law, JM; Law, SH; Mondon, JA, 2010
)
0.36
" Finally, we demonstrate that FXR agonists do not stimulate migration in breast cancer cell lines, an important potential adverse effect."( Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential.
Alasmael, N; Meira, LB; Mohan, R; Plant, NJ; Swales, KE, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" The SEDDS formulation was found to greatly improve the oral bioavailability of GW4064, and permitted the evaluation of FXR agonist target efficacy."( A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys.
Chiang, PC; Ghosh, S; Heitmeier, MR; Thompson, DC, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" The preclinical ADME properties of LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advanced to the clinic for evaluation in humans."( Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Agejas Francisco, J; Bocchinfuso, WP; Bueno, AB; Cannady, EA; Cox, A; Genin, MJ; Jones, TM; Manninen, PR; Michael, LF; Michael, MD; Montrose-Rafizadeh, C; Raddad, E; Reidy, C; Stille, JR, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency33.55210.125919.1169125.8920AID2549; AID504841
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
Bloom syndrome protein isoform 1Homo sapiens (human)Potency31.62280.540617.639296.1227AID2528
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency70.79460.010039.53711,122.0200AID1469
tyrosine-protein kinase YesHomo sapiens (human)Potency43.43200.00005.018279.2586AID686947
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency5.62340.00798.23321,122.0200AID2546
DNA polymerase kappa isoform 1Homo sapiens (human)Potency29.93490.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency12.58930.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vitamin D3 receptorHomo sapiens (human)IC50 (µMol)10.00000.00000.43746.4300AID1664090
Bile acid receptorHomo sapiens (human)IC50 (µMol)0.06500.01834.560310.0000AID1142317; AID1799083; AID352177; AID568244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)EC50 (µMol)0.06500.00010.23283.2000AID577553
Bile acid receptorMus musculus (house mouse)EC50 (µMol)2.00000.15202.04315.0000AID352180
Bile acid receptorHomo sapiens (human)EC50 (µMol)0.43900.00401.419110.0000AID1138961; AID1138963; AID1166179; AID1166180; AID1168707; AID1176270; AID1176271; AID1232938; AID1266951; AID1266953; AID1311154; AID1311156; AID1477476; AID1477478; AID1546885; AID1546886; AID1614980; AID1633315; AID1664089; AID1669479; AID1698077; AID1727455; AID1761036; AID1798115; AID1799081; AID1799082; AID1893165; AID1900734; AID1900736; AID1917274; AID240068; AID240176; AID294203; AID341960; AID341962; AID352178; AID352765; AID352768; AID433264; AID433266; AID494859; AID494861; AID494863; AID568245; AID577551; AID577553; AID622453; AID622454; AID662692; AID694036; AID72526; AID72529; AID755457; AID755458; AID755459; AID755462
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile acid receptorHomo sapiens (human)Activity0.06400.06400.06400.0640AID1138962
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (91)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
negative regulation of DNA-templated transcriptionVitamin D3 receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
cell morphogenesisVitamin D3 receptorHomo sapiens (human)
skeletal system developmentVitamin D3 receptorHomo sapiens (human)
calcium ion transportVitamin D3 receptorHomo sapiens (human)
intracellular calcium ion homeostasisVitamin D3 receptorHomo sapiens (human)
lactationVitamin D3 receptorHomo sapiens (human)
negative regulation of cell population proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of gene expressionVitamin D3 receptorHomo sapiens (human)
negative regulation of keratinocyte proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activityVitamin D3 receptorHomo sapiens (human)
positive regulation of bone mineralizationVitamin D3 receptorHomo sapiens (human)
phosphate ion transmembrane transportVitamin D3 receptorHomo sapiens (human)
bile acid signaling pathwayVitamin D3 receptorHomo sapiens (human)
mRNA transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
positive regulation of keratinocyte differentiationVitamin D3 receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
decidualizationVitamin D3 receptorHomo sapiens (human)
intestinal absorptionVitamin D3 receptorHomo sapiens (human)
apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
regulation of calcidiol 1-monooxygenase activityVitamin D3 receptorHomo sapiens (human)
mammary gland branching involved in pregnancyVitamin D3 receptorHomo sapiens (human)
vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
response to bile acidVitamin D3 receptorHomo sapiens (human)
multicellular organism developmentVitamin D3 receptorHomo sapiens (human)
cell differentiationVitamin D3 receptorHomo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (42)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
DNA-binding transcription factor activityVitamin D3 receptorHomo sapiens (human)
vitamin D response element bindingVitamin D3 receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificVitamin D3 receptorHomo sapiens (human)
DNA bindingVitamin D3 receptorHomo sapiens (human)
nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
protein bindingVitamin D3 receptorHomo sapiens (human)
zinc ion bindingVitamin D3 receptorHomo sapiens (human)
bile acid nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
nuclear retinoid X receptor bindingVitamin D3 receptorHomo sapiens (human)
calcitriol bindingVitamin D3 receptorHomo sapiens (human)
lithocholic acid bindingVitamin D3 receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingVitamin D3 receptorHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleoplasmVitamin D3 receptorHomo sapiens (human)
cytosolVitamin D3 receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexVitamin D3 receptorHomo sapiens (human)
chromatinVitamin D3 receptorHomo sapiens (human)
receptor complexVitamin D3 receptorHomo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (181)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1633339Agonist activity at FXR in human HepG2 cells assessed as upregulation of SHP mRNA level at 10 uM after 18 hrs by RT-PCR assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID352784Total clearance in iv dosed rat2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
AID72527Relative recruitment of SRC1 peptide to Farnesoid X receptor (FXR) where CDCA=100%2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
AID1142321Antagonist activity at human GST-tagged FXR at 10 uM after 20 mins by TR-FRET assay relative to control2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.
AID1414413Reduction in lipid accumulation in mouse 3T3L1 cells at 10 uM by Oil Red O staining-based absorbance method relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
Structure-guided design and synthesis of isoflavone analogs of GW4064 with potent lipid accumulation inhibitory activities.
AID303509Decrease in CYP7A1 gene expression in human HepG2 cells at 1 uM after 18 hrs by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1232959Partial agonist activity at FXR in human HepG2 cells assessed as induction of BSEP gene expression at 3 uM after 24 hrs by qRT-PCR analysis (Rvb = 100%)2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
AID294203Agonistic activity at FXR in HEK293 cells by GAL4 transactivation activity2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
AID1313862Induction of FXR-mediated Akt-phosphorylation at S473 site in serum-starved wild-type mouse primary hepatocytes at 10 uM measured after 10 mins by western blot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID1900734Agonist activity at FXR-LBD (unknown origin) assessed as induction of coactivator SRC-1 peptide recruitment measured by TR-FRET assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.
AID1664095Agonist activity at FXR in human HuH7 cells assessed as as increase in BSEP mRNA expression at 0.01 to 1 uM by RT-qPCR analysis
AID622453Agonist activity at human amino-terminal polyhistidine-tagged FXR alpha LBD (amino acids 237 to 472) assessed as cofactor peptide SRC-1 interaction with receptor ligand binding domain after 2 hrs by FRET assay2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene.
AID1414417Transactivation of FXR (unknown origin) at 10 uM by cell-based dual luciferase reporter gene assay2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
Structure-guided design and synthesis of isoflavone analogs of GW4064 with potent lipid accumulation inhibitory activities.
AID1664097Agonist activity at FXR in human HuH7 cells assessed as as increase in OSTalpha mRNA expression at 0.01 to 1 uM by RT-qPCR analysis
AID755458Binding affinity to human GTS-tagged FXR LBD using fluorescein-tagged SRC2-2 after 15 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1313868Induction of Akt-phosphorylation in serum-starved fxr-/- mouse primary hepatocytes assessed as increase in GSK-3beta phosphorylation at 10 uM measured after 10 mins by western blot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID1669505Stability in Sprague-Dawley rat liver microsomes assessed as remaining parent compound level at 10 uM presence of NADPH regenerating system by HPLC analysis2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Design and Structural Optimization of Dual FXR/PPARδ Activators.
AID1761038Agonist activity at FXR (unknown origin)/human RXR heterodimer expressing in human HepG2 cells co-expressing pCMV gal assessed luciferase activity measured after 24 hrs by by cell based luciferase transactivation assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.
AID568246Agonist activity at Gal4-fused human FXR by luciferase reporter gene transactivation assay relative to GW40642011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.
AID1669479Activation of human FXR LBD expressed in HEK293T cells assessed as induction of receptor activation incubated for 12 to 14 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Design and Structural Optimization of Dual FXR/PPARδ Activators.
AID1698076Agonist activity at GST-tagged human FXR LBD assessed as induction of biotinylated coactivator SRC-1 peptide recruitment measured after 2 hrs by streptavidin-conjugated AlphaScreen assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
AID1166179Agonist activity at FXR (unknown origin) by coactivator recruitment assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID1669497Activation of human FXR LBD expressed in HEK293T cells assessed as induction of receptor activation at 1 uM incubated for 12 to 14 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Design and Structural Optimization of Dual FXR/PPARδ Activators.
AID568244Displacement of radioligand from human FXR by scintillation proximity assay2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.
AID1451531Transactivation of FXR in human HepG2 cells assessed as SHP mRNA expression at 3 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID1138963Agonist activity at FXR (unknown origin) by reporter gene assay2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
AID657098Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as decrease in [3H]taurocholate accumulation preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scint2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
AID1917283Clearance in mouse at 20 mg/kg, po or 5 mg/kg, iv2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID1232938Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
AID1893165Agonist activity at human FXR transfected in CHO-K1 cells coexpressed with beta-galactosidase incubated for 3 to 16 hrs by PathHunter chemiluminescence based assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Discovery of (
AID1727455Agonist activity at human FXR expressed in HEK293T cells co-transfected with BSEP plasmid assessed as receptor transactivation after 24 hrs by BSEP-luciferase reporter gene assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
AID1266951Agonist activity at human FXR transfected in HEK293 cells assessed as transcriptional activity by luciferase reporter gene assay2015Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
AID622452Agonist activity at human amino-terminal polyhistidine-tagged FXR alpha LBD (amino acids 237 to 472) assessed as maximum efficacy measuring cofactor peptide SRC-1 interaction with receptor ligand binding domain after 2 hrs by FRET assay relative to GW40642011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene.
AID1917281AUCinfinity in mouse at 20 mg/kg, po2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID494864Agonist activity at human full length FXR transfected in HEK293 cells coexpressing pTRexDest/pGL2promotor assessed as luciferase activity by direct reporter cellular assay relative to GW-40642010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
AID1917285Half life in mouse at 20 mg/kg, po2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID662693Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay relative to GW40642012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.
AID1398009Activation of FXR in human HepG2 cells assessed as downregulation of SREBP-1c mRNA expression at 10 uM by RT-PCR method2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study.
AID303503Activation of SHP gene expression in human Huh7 cells at 1 uM after 18 hrs by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1633318Half life in CD1 mouse liver microsomes at 1 uM up to 40 mins by LC-MS/MS method2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID352180Agonist activity at mouse chimeric FXR assessed as receptor transactivation by luciferase transcriptional reporter gene assay2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
AID1633319Metabolic stability in CD1 mouse liver microsomes assessed as compound remaining at 1 uM up to 40 mins by LC-MS/MS method relative to control2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID1313856Induction of FXR-mediated Akt-phosphorylation at S473 site in serum-starved human HepG2 cells at 10 uM measured after 10 mins by western blot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID1313859Induction of FXR-mediated Akt-phosphorylation in serum-starved human HepG2 cells assessed as increase in GSK-3beta-phosphorylation at 10 uM measured after 10 mins by western blot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID303499Activation of BSEP gene expression in human Huh7 cells at 1 uM after 18 hrs by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1876315Agonist activity at GST-tagged FXR-LBD (unknown origin) using N-terminal FITC-labeled SRC-1 box2 coactivator peptide by fluorescence polarization assay2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Structure-Activity Relationship Studies of Trisubstituted Isoxazoles as Selective Allosteric Ligands for the Retinoic-Acid-Receptor-Related Orphan Receptor γt.
AID577554Agonist activity at human FXR LBD iexpressed in monkey CV-1 cells assessed as transactivation of luciferase reporter gene expression relative to GW 40642011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
AID577551Agonist activity at human FXR LBD assessed as SRC1 peptide recruitment by FRET assay2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
AID577591Binding affinity to human FXR by X-ray crystallography2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
AID1313854Induction of FXR-mediated SHP mRNA expression in serum-starved human HepG2 cells at 10 uM measured after overnight incubation by qPCR analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID294206Inhibition of FXR in HEK293 cells in presence of CDCA at 100 uM by GAL4 transactivation activity2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
AID1614980Agonist activity FXR (unknown origin)2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1633317Intrinsic clearance in CD1 mouse liver microsomes at 1 uM up to 40 mins by LC-MS/MS method2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID352177Displacement of radioligand from human FXR by scintillation proximity assay2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
AID494863Agonist activity at human full length FXR transfected in HEK293 cells coexpressing pTRexDest/pGL2promotor assessed as luciferase activity by direct reporter cellular assay2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
AID755457Binding affinity to human GTS-tagged FXR LBD using fluorescein-tagged SRC2-2 after 30 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1138961Agonist activity at FXR (unknown origin) by coactivator recruitment assay2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
AID1669506Toxicity in human HepG2 cells assessed as reduction in cell viability up to 100 uM incubated for 48 hrs by WST1 assay2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Design and Structural Optimization of Dual FXR/PPARδ Activators.
AID1142317Antagonist activity at human GST-tagged FXR after 20 mins by TR-FRET assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.
AID1633316Aqueous solubility of compound in phosphate buffer at pH 7.4//MeOH after 24 hrs by LC-MS/MS method2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID352181Agonist activity at mouse chimeric FXR assessed as receptor transactivation by luciferase transcriptional reporter gene assay relative to GW-40642009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
AID352179Agonist activity at chimeric FXR assessed as receptor transactivation by luciferase transcriptional reporter gene assay relative to GW-40642009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
AID1727457Cytotoxicity against human HepG2 cells assessed as cell viability upto 40 uM after 48 hrs by MTT assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
AID1398008Activation of FXR in human HepG2 cells assessed as upregulation of FXR mRNA expression at 10 uM by RT-PCR method2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study.
AID433264Induction of SRC1 coactivator peptide binding to ligand binding domain of human FXR by FRET assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
FXR agonist activity of conformationally constrained analogs of GW 4064.
AID1451549Transactivation of FXR in human HepG2 cells assessed as FGF19 mRNA expression at 3 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID352769Agonist activity at human FXR transfected in african green monkey CV1 cells by luciferase reporter gene transient transfection assay relative to GW-40642009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
AID1761039Agonist activity at FXR (unknown origin)/human RXR heterodimer expressing in human HepG2 cells co-expressing pCMV gal assessed luciferase activity measured after 24 hrs by by cell based luciferase transactivation assay relative to GW60642021European journal of medicinal chemistry, Feb-05, Volume: 211Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.
AID568245Agonist activity at Gal4-fused human FXR by luciferase reporter gene transactivation assay2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.
AID72530Farnesoid X-activated receptor activity compared to 50 uM chenodeoxycholic acid (CDCA)2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Identification of a chemical tool for the orphan nuclear receptor FXR.
AID1761036Agonist activity at FXR-LBD (unknown origin) assessed by ligand binding ability incubated for 3 hrs in absence of light measured by TR-FRET Coactivator assay2021European journal of medicinal chemistry, Feb-05, Volume: 211Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.
AID1414412Cytotoxicity against mouse 3T3L1 cells assessed as effect on cell viability at 10 uM after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
Structure-guided design and synthesis of isoflavone analogs of GW4064 with potent lipid accumulation inhibitory activities.
AID1313849Binding affinity to GST-tagged human FXR at 1 uM in presence of FXR agonist DY246 measured after 15 mins by TR-FRET assay2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID1451535Transactivation of FXR in human HepG2 cells assessed as CYP7A1 mRNA expression at 3 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID662691Enhancement of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 10 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scint2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.
AID1313866Induction of FXR-mediated Akt-phosphorylation in serum-starved wild-type mouse primary hepatocytes assessed as increase in GSK-3beta phosphorylation at 10 uM measured after 10 mins by western blot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID1664093Antagonist activity at human VDR transfected in HEK293T cells measured after 24 hrs by luciferase reporter gene assay relative to control
AID755462Agonist activity at human FXR assessed as recruitment of SRC1 peptide by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1917279AUC (0 to t) in mouse at 20 mg/kg, po2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID755459Binding affinity to human GTS-tagged FXR LBD using fluorescein-tagged SRC2-2 after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1311156Agonist activity at C-terminal Gal4-tagged human FXR (187 to 472 residues) expressed in HEK-293 cells co-expressing pFRluc by mammalian one hybrid assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.
AID1698077Agonist activity at human FXR expressed in HEK293 cells measured after 18 hrs by steady-glo luciferase reporter gene assay2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
AID243397Efficacy for human Farnesoid X receptor in FRET assay2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
AID1917278AUCinfinity in mouse at 5 mg/kg, iv2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID1727458Agonist activity at human FXR in HepG2 cells assessed as nuclear translocation at 1 uM for 16 hrs by immunofluorescence analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
AID240176Binding affinity for human Farnesoid X receptor in FRET assay2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
AID1917274Agonist activity at FXR in HEK293T cells assessed as transcriptional activity by measuring fluorescence intensity by luciferase reporter assay2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID1664096Agonist activity at FXR in human HuH7 cells assessed as as increase in SHP mRNA expression at 0.01 to 1 uM by RT-qPCR analysis
AID1451527Transactivation of FXR in human HepG2 cells assessed as BSEP mRNA expression at 3 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID1917277AUC (0 to t) in mouse at 5 mg/kg, iv2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID622454Agonist activity at human FXR LBD transfected in african green monkey CV1 cells after overnight incubation by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene.
AID679670TP_TRANSPORTER: Northern blot from HepG2 cells2002The Journal of biological chemistry, Jan-25, Volume: 277, Issue:4
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.
AID303501Activation of BSEP gene expression in human HepG2 cells at 1 uM after 18 hrs by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID352765Agonist activity at human FXR transfected in african green monkey CV1 cells by luciferase reporter gene transient transfection assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
AID662692Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.
AID1669504Aqueous solubility in pH 8 buffer by HPLC analysis2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Design and Structural Optimization of Dual FXR/PPARδ Activators.
AID1311154Agonist activity at GST-tagged FXR LBD (187 to 472 residues) (unknown origin) assessed as FXR interaction with b-CPSSHSSLTERHKILHRLLQEGSPS-COOH by FRET assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.
AID1166208Agonist activity at FXR in human HepG2 cells assessed as induction of BSEP mrNA expression at 3 uM by quantitative PCR method2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID494860Agonist activity at human GST-fused FXR LBD assessed as cofactor peptide interaction with receptor ligand binding domain by FRET assay relative to GW-40642010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
AID341960Agonist activity at FXR assessed as receptor-SRC-1 peptide interaction by FRET assay2008Bioorganic & medicinal chemistry letters, 08-01, Volume: 18, Issue:15
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.
AID494859Agonist activity at human GST-fused FXR LBD assessed as cofactor peptide interaction with receptor ligand binding domain by FRET assay2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
AID1633314Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotin-labeled SRC-1 recruitment at 5 uM after 30 mins by Alpha Screen assay relative to 6-ECDCA2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID679484TP_TRANSPORTER: Northern blot in vitro, primary hepatocytes2002The Journal of biological chemistry, Jan-25, Volume: 277, Issue:4
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.
AID1166180Agonist activity at FXR (unknown origin) by reporter gene assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
AID1719703Metabolic stability in Sprague-Dawley rat liver microsomes assessed as compound degradation at 10 uM incubated for 60 min by HPLC analysis2021ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2
A New FXR Ligand Chemotype with Agonist/Antagonist Switch.
AID72526Effective concentration against Farnesoid X receptor (FXR)2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
AID1176271Agonist activity at FXR (unknown origin) transfected into african green monkey CV1 cells assessed as ligand-mediated transcription by luciferase reporter/ transient transfection assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists.
AID694036Agonist activity at FXR2012Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22
Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking.
AID352178Agonist activity at chimeric FXR assessed as receptor transactivation by luciferase transcriptional reporter gene assay2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
AID1633327Hepatoprotective activity against APAP-induced acute liver injury in C57BL/6N mouse assessed as reduction in plasma AST levels at 30 mg/kg, po administered 45 mins after APAP challenge2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID72529Ligand dependent recruitment of SRC1(676-700) peptide to human Farnesoid X-activated receptor by fluorescence resonance energy transfer assay2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Identification of a chemical tool for the orphan nuclear receptor FXR.
AID1176270Agonist activity at FXR (unknown origin) assessed as ligand-mediated interaction of the SRC1 peptide with protein LBD by FRET assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists.
AID1633313Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotin-labeled SRC-1 recruitment at 5 uM after 30 mins by Alpha Screen assay relative to CDCA2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID1664090Antagonist activity at human VDR transfected in HEK293T cells measured after 24 hrs by luciferase reporter gene assay
AID657097Restoration of human BSEP E297G mutant trafficking to cell membrane in MDCK2 cells co-expressing NTCP assessed as accumulation of [3H]taurocholate at 10 uM preincubated for 24 hrs prior incubation with [3H]taurocholate measured after 2 hrs by liquid scint2012Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9
Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.
AID1669494Activation of human PPAR-delta LBD expressed in HEK293T cells assessed as induction of receptor activation up to 10 uM incubated for 12 to 14 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Design and Structural Optimization of Dual FXR/PPARδ Activators.
AID1633315Transactivation of human FXR (unknown origin) expressed in HepG2 cells co-expressing pSG5RXR/pGL4.70 after 24 hrs post transfection by luciferase reporter gene assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID679819TP_TRANSPORTER: Northern blot in vitro, primary hepatocytes2002The Journal of biological chemistry, Jan-25, Volume: 277, Issue:4
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.
AID1477478Agonist activity at human FXR expressed in HEK293T cells assessed as BSEP promoter driven cellular transcriptional activity after 24 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
AID577552Agonist activity at human FXR LBD assessed as SRC1 peptide recruitment by FRET assay relative to GW 40642011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
AID622455Agonist activity at human FXR LBD transfected in african green monkey CV1 cells assessed as maximum efficacy after overnight incubation by luciferase reporter gene assay relative to GW40642011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene.
AID1900736Agonist activity at human FXR expressed in HEK293T cells by luciferase reporter assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.
AID1313850Binding affinity to GST-tagged human FXR at 1 uM in presence of FXR agonist DY246 measured after 25 mins by TR-FRET assay2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID1664091Agonist activity at human FXR expressed in human HuH7 cells by luciferase reporter gene assay relative to control
AID1546888Half life in rat2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID1546886Agonist activity at FXR (unknown origin) by cell based assay2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID1633328Hepatoprotective activity against APAP-induced acute liver injury in C57BL/6N mouse assessed as reduction in plasma ALT levels at 30 mg/kg, po administered 45 mins after APAP challenge2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.
AID1398007Cytotoxicity against human HepG2 cells assessed as decrease in cell viability at 5 to 80 uM after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study.
AID433266Increase in human FXR-mediated transient transcription of luciferase reporter gene transfected in african green monkey CV1 cells2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
FXR agonist activity of conformationally constrained analogs of GW 4064.
AID1917291Oral bioavailability in mouse at 20 mg/kg2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID1761037Agonist activity at FXR-LBD (unknown origin) assessed as maximum activation incubated for 3 hrs in absence of light measured by TR-FRET Coactivator assay in relative to GW40642021European journal of medicinal chemistry, Feb-05, Volume: 211Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist.
AID303510Activation of IBABP gene expression in human Caco-2 cells at 1 uM after 6 days by RT-PCR2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1266953Agonist activity at recombinant His-tagged human FXR ligand binding domain assessed as SRC-1 coactivator recruitment after 4 hrs by luminescence analysis2015Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24
Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
AID303495Activity at human VP16-FXR assessed as activation of SRC1 interaction domain 2 recruitment at 1 uM by mammalian two-hybrid assay2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
AID1664089Agonist activity at human FXR expressed in human HuH7 cells by luciferase reporter gene assay
AID1313864Induction of Akt-phosphorylation at S473 site in serum-starved fxr-/- mouse primary hepatocytes at 10 uM measured after 10 mins by western blot analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
AID494861Agonist activity at human GST-fused FXR LBD expressed in HEK293 cells coexpressing GAL4-DNA bindig domain and pFRluc by mammalian one-hybrid assay2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
AID577553Agonist activity at human FXR LBD iexpressed in monkey CV-1 cells assessed as transactivation of luciferase reporter gene expression2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
AID1142320Cytotoxicity against HEK293T cells expressing FXR and beta-lactamase genes assessed as inhibition of cell viability at 40 uM after 16 hrs by CellTiter-Glo luminescent assay relative to control2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.
AID240068Activation of human farnesoid X receptor2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Farnesoid X receptor: from structure to potential clinical applications.
AID1917289Cmax in mouse at 20 mg/kg, po2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID1917287Tmax in mouse at 20 mg/kg, po2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists.
AID494862Agonist activity at human GST-fused FXR LBD expressed in HEK293 cells coexpressing GAL4-DNA bindig domain and pFRluc by mammalian one-hybrid assay relative to GW-40642010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
AID1458348Cytotoxicity against human HepG2 cells at 50 uM after 48 hrs by WST-1 assay2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Nonacidic Farnesoid X Receptor Modulators.
AID1458345Lipophilicity, logD of compound at pH 7.4 by LC-MS analysis2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Nonacidic Farnesoid X Receptor Modulators.
AID352182Permeability by PAMPA method2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
AID1138962Binding affinity to FXR (unknown origin) by scintillation proximity assay2014Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8
Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
AID1546885Agonist activity at FXR (unknown origin)2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID1398010Activation of FXR in human HepG2 cells assessed as upregulation of SHP mRNA expression at 10 uM by RT-PCR method2018Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17
Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study.
AID352764Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assay relative to GW-40642009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
AID341962Agonist activity at FXR expressed in african green monkey CV1 cells by luciferase reporter transient transfection assay2008Bioorganic & medicinal chemistry letters, 08-01, Volume: 18, Issue:15
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.
AID1451542Transactivation of FXR in human HepG2 cells assessed as SREBP1c mRNA expression at 3 uM after 8 to 16 hrs by SYBR green based qRT-PCR analysis relative to DMSO control2017Journal of medicinal chemistry, 09-28, Volume: 60, Issue:18
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
AID680942TP_TRANSPORTER: Taq-Man PCR in vitro, primary hepatocytes2002The Journal of biological chemistry, Aug-30, Volume: 277, Issue:35
Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity.
AID1168707Agonist activity at human FXR expressed in HEK293 cells by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID1900735Agonist activity at FXR-LBD (unknown origin) assessed as induction of coactivator SRC-1 peptide recruitment measured by TR-FRET assay in relative to GW40642022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.
AID1546887Oral bioavailability in rat2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID1477476Agonist activity at recombinant human GST-tagged FXR ligand binding domain (193 to 472 residues) expressed in baculovirus infected insect cells assessed as induction of interaction with biotin labelled SRC-1 after 1 hr by HTRF assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
AID1900737Agonist activity at human FXR expressed in HEK293T cells by luciferase reporter assay in relative to GW40642022European journal of medicinal chemistry, Feb-15, Volume: 230Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis.
AID352768Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347171Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1798115Cotransfection Assay from Article 10.1016/j.bmc.2007.01.046: \\Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.\\2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
AID1799083Scintillation Proximity Assay (IC50) and Cell-Based Transactivation Assay (EC50) from Article 10.1016/j.bmcl.2009.03.008: \\Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.\\2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
AID1799081FXR Ligand-Seeking Assay from Article 10.1016/j.bmcl.2008.06.073: \\Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.\\2008Bioorganic & medicinal chemistry letters, 08-01, Volume: 18, Issue:15
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.
AID1799082FXR Transient Transfection Assay from Article 10.1016/j.bmcl.2008.06.073: \\Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.\\2008Bioorganic & medicinal chemistry letters, 08-01, Volume: 18, Issue:15
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.
AID1346766Human Farnesoid X receptor (1H. Liver X receptor-like receptors)2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Identification of a chemical tool for the orphan nuclear receptor FXR.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (221)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's55 (24.89)29.6817
2010's133 (60.18)24.3611
2020's33 (14.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.72 (24.57)
Research Supply Index5.41 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index37.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.45%)5.53%
Reviews8 (3.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other213 (95.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]